You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Macrophage–Erythrocyte Interactions in Sickle Cell Disease Erythropoiesis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor: Renata Sesti-Costa , Fernando F. Costa , Nicola Conran

Sickle cell disease (SCD) is an inherited blood disorder caused by a β-globin gene point mutation that results in the production of sickle hemoglobin that polymerizes upon deoxygenation, causing the sickling of red blood cells (RBCs). Macrophages participate in extravascular hemolysis by removing damaged RBCs, hence preventing the release of free hemoglobin and heme, and triggering inflammation. Upon erythrophagocytosis, macrophages metabolize RBC-derived hemoglobin, activating mechanisms responsible for recycling iron, which is then used for the generation of new RBCs to try to compensate for anemia. In the bone marrow, macrophages can create specialized niches, known as erythroblastic islands (EBIs), which regulate erythropoiesis. Anemia and inflammation present in SCD may trigger mechanisms of stress erythropoiesis, intensifying RBC generation by expanding the number of EBIs in the bone marrow and creating new ones in extramedullary sites. 

  • erythroblastic islands
  • hemolysis
  • iron
  • leukocytes
  • phagocytosis
  • red blood cells

1. Introduction

A single point mutation in the gene that encodes the beta globin chain results in the production of abnormal sickle hemoglobin (HbS) and sickle cell disease (SCD) [1]. SCD is encountered as homozygous sickle cell disease (HbSS), termed sickle cell anemia (SCA), or in compound heterozygosity with another hemoglobin gene mutation (e.g., HbC disease or beta thalassemia) [2], where the polymerization of HbS, when deoxygenated, and the consequent formation of hemoglobin fibers causes the sickling of red blood cells (RBCs), which is the primary cause of SCD pathophysiology [3]. RBC sickling incurs multiple disease mechanisms that ultimately trigger vaso-occlusion in blood vessels and end-organ damage [4]. The clinical complications of SCD are many and varied, and they can be classified as chronic (e.g., chronic pain, chronic kidney disease, sickle retinopathy, avascular necrosis) or acute (e.g., painful vaso-occlusive episodes, acute chest syndrome, stroke) in nature [4][5]. Of all the clinical complications of SCD, painful vaso-occlusive episodes and anemia, caused principally by continuous hemolysis, are considered the most characteristic of SCD [6].

2. Macrophage–Erythrocyte Interactions in Sickle Cell Disease Erythropoiesis

Erythroid production is directly correlated to EBI number; thus, the EBI microenvironment is crucial for events of erythropoiesis. Macrophages present in these structures play several key regulatory roles in the process via both contact- and soluble factor-dependent mechanisms. These cells are able to induce erythroblast proliferation and survival, provide iron for hemoglobin synthesis, and engulf the nucleus expelled during erythroblast enucleation [7][8][9].
Although EBI macrophages are not a homogeneous population, they display an M2-like phenotype, with the expression of CD206 and CD169, and they exhibit an anti-inflammatory profile [7][10]. These anti-inflammatory macrophages express CD163, which scavenges the hemoglobin–haptoglobin complex besides acting as an adhesion receptor to erythroblasts, although its ligand is still not known [11]. The island’s integrity is achieved by the attachment of macrophages to erythroblasts, which is mediated by several adhesion molecules, such as VCAM-1, αV integrin, ephrin-B2, and Emp expressed by EBI macrophages, which in turn bind to α4β1 integrin, ICAM-4, EphB4, and Emp, expressed by erythroblasts, respectively. Each molecule of these sets of receptors plays a role in the EBI structure, as demonstrated by mice models. The pharmacological inhibition of the interaction between either α4β1 integrin with VCAM-1 or ephrin-B2 with EphB4, as well as the depletion of ICAM-4, in mice results in lower numbers of EBI and the dissociation of erythroblasts from macrophages [12][13][14]; furthermore, the depletion of Emp is reportedly lethal due to severe anemia in mice fetuses [15]. Additionally, a secreted form of ICAM-4, ICAM-4S, was found to be released by orthochromatic erythroblasts and reticulocytes; this secreted molecule competes with the membrane-bound molecule by binding to αV integrin on macrophages [16], potentially weakening reticulocyte–macrophage interactions and releasing them from the EBI niche toward the sinusoids.
These molecule sets seem to be heterogeneously distributed among EBI macrophages throughout the bone marrow [17], which might represent phenotypic and functional differences of EBIs located at distinct zones. For instance, macrophages scattered through the bone marrow are adhered to proerythroblasts and early erythroblasts, whereas macrophages close to sinusoids are attached to cells in the late stages of differentiation, such as polychromatic and orthochromatic erythroblasts [18]. It is not known, though, whether the macrophages are either different cells or cells in a distinct stage of maturation that migrate toward sinusoids upon erythropoiesis progression. Furthermore, some adhesion molecules have distinct levels of contributions to steady-state and stress erythropoiesis, indicating heterogeneity in the expression of surface molecules between EBI macrophages from physiological (bone marrow) and stress (spleen and liver) tissues. Mutations in the α4 integrin gene inhibit stress erythropoiesis, as illustrated by the impairment of recovery after anemia induced by hemolysis, but these mutations have little effect on steady-state erythropoiesis [19]. Additionally, it has been shown that the hematopoietic niche of SCD patients is extremely altered, with changes in the number and frequency of different cell progenitors and with modified EBI structure [20], which is possibly due to changes in adhesion protein expression.
It has been demonstrated that circulating monocytes, particularly the intermediate CD14highCD16+ cells, are able to boost the differentiation of CD34+ cells to erythrocytes in vitro in a contact-independent manner, increasing expansion and reducing the death of CD34+ cells before they enter the erythroblast stage. Like EBI macrophages, these monocytes express CD206, CD163 and CD169, enabling them to interact with erythroid cells and, in the presence of glucocorticoid, promote erythropoiesis and engulf the nucleus that is expelled during the erythroid differentiation process [10][21]. In SCD, where the number of circulating monocytes is elevated, these cells might play an important role in stress erythropoiesis since the spleen is frequently dysfunctional. In fact, patrolling monocytes from SCD patients were seen to phagocyte circulating RBCs [22]. Whether the iron recycled by those monocytes can be used for the synthesis of hemoglobin by the circulating erythroblasts present in SCD patients is a question to be investigated.
Between the orthochromatic erythroblast and reticulocyte stages of differentiation, erythroid cells expel the nucleus and most of their organelles, which are then cleared by EBI macrophages, promoting erythroid maturation. Indeed, the depletion of EBIs macrophages in mice impaired the elimination of mitochondria, resulting in reduced mature RBCs [23]. The extruded nuclei were shown to be recognized by their externalized phosphatidylserine (PS) and reduction in PS recognition, as occurs in MFG-E8 mutant mice that display impaired clearance of nuclei from erythroblasts [8]. Notably, the retention of mitochondria has been detected in both reticulocytes and RBCs in SCD patients [24]. The mitochondria in mature RBCs have been shown to be metabolically competent and were associated with high levels of ROS in SCD. In addition, mitochondria-containing RBCs are able to activate immune responses in vitro, indicating that the retention of mitochondria may play a role in the complications of SCD [25]. Together with the presence of circulating nucleated RBCs, the retention of mitochondria in RBCs suggests a defect in the elimination process by EBI macrophages in addition to the weakness in the macrophage–erythroblast interaction. The digestion of the nuclei and mitochondrial DNA collected from erythroid cells is essential for the survival of EBI macrophages and is performed by DNase II, whose absence in the KO mice model causes the death of the macrophages due to the accumulation of intracellular non-degraded DNA, resulting in lethal impairment in erythropoiesis and anemia [26].
Erythropoiesis is supported by the iron provision of EBI macrophages for hemoglobin synthesis. Macrophages recycle iron from erythrophagocytosis and the clearance of hemoglobin/Hp and heme/Hpx complexes through HMOX-1 activity, which is up-regulated in SCD and catabolizes heme to equimolar amounts of iron, biliverdin and carbon monoxide (CO). The role of HMOX-1 in stress erythropoiesis is essential, as a drop in its activity impairs the maturation of erythroid cells [27][28]. It has been demonstrated that besides iron, CO can support RBC maturation, at least in cultures of the erythroid cell lineage K562 [29]. Recycled iron can have one of two destinations, either stored as ferritin or exported by ferroportin and transported bound to transferrin (Trf) [30]. Erythroblasts can internalize the iron/Trf complex through their Trf receptor (CD71). In addition, macrophages have been reported to secrete ferritin in macrophage/erythroblast cocultures, which is then captured by erythroblasts [31]. The systemic control of iron load in SCD is complex, as hepcidin is secreted in response to iron and inflammation, whereas it is down-regulated by hypoxia and erythropoiesis. Additionally, recent findings have shown that despite anemic conditions, treatment with a ferroportin inhibitor improved some aspects of SCD pathology by restricting iron to RBCs and consequently reducing the HbS concentration [32]. Thus, a better understanding of iron metabolism, specifically in the EBI niche, is still needed and would provide insights for novel therapeutic approaches.
KLF1 (Kruppel Like Factor 1) is the transcription factor that best defines EBI macrophages. It is responsible for up-regulation of DNase II and the expression of VCAM-1, CD163, CD169, enabling the macrophage to promote erythroid development [33][34][35]. In the absence of KLF1 expression, mice have reduced DNase II and die of severe anemia [36][37]. KLF1 also regulates the expression of IL-33, which is a cytokine that promotes the maturation of RBCs [35]. Additionally, IL-33 differentiates monocytes into macrophages involved in erythrophagocytosis and iron recycling [38] and has been shown to be elevated in SCD patients [39]. Other soluble factors found to be secreted by EBI macrophages are insulin-like growth factor (IGF1) and IL-18 [33]. IGF1 was shown to increase erythropoiesis by binding to the IGF1R expressed by erythroblasts in several development stages [40], whereas the possible role of IL-18 in erythropoiesis has still not been investigated, even though the expression of IL-18R has been detected in erythroid lineage cells and the production of IL-18 may be stimulated in SCD by heme-activated inflammasome formation [41]. Although the presence of systemic levels of these factors in SCD has been investigated, the contribution of EBI macrophages to the production and the dynamics of these mechanisms specifically in the EBI niche in SCD patients still needs clarification.
Depletion of CD169+ macrophages in mice models of polycythemia vera and β-thalassemia, which both display activated stress erythropoiesis, was able to reverse some aspects of the diseases pathology, such as the defect in erythroid development and lifespan as well as splenomegaly [7][42], revealing EBI macrophages as possible targets for future therapies for stress and ineffective erythropoiesis in disorders such as SCD. The secreted factors induced in the EBI niche should be investigated as an option to enhance the proliferation and maturation of RBCs, whereas the signaling molecules that are modulated upon stress erythropoiesis are a potential target for pharmaceutical approaches. Furthermore, uncovering the mechanisms by which EBI macrophages influence the switch to HbF production in erythroid cells would shed light on other options for HbF-inducing treatments to improve the clinical manifestations of SCD patients.

This entry is adapted from the peer-reviewed paper 10.3390/ijms24076333

References

  1. Kato, G.J.; Piel, F.B.; Reid, C.D.; Gaston, M.H.; Ohene-Frempong, K.; Krishnamurti, L.; Smith, W.R.; Panepinto, J.A.; Weatherall, D.J.; Costa, F.F.; et al. Sickle cell disease. Nat. Rev. Dis. Prim. 2018, 4, 18010.
  2. Steinberg, M.H. Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. J. Clin. Med. 2020, 9, 3782.
  3. Hofrichter, J.; Ross, P.D.; Eaton, W.A. Kinetics and mechanism of deoxyhemoglobin S gelation: A new approach to understanding sickle cell disease. Proc. Natl. Acad. Sci. USA 1974, 71, 4864–4868.
  4. Rees, D.C.; Williams, T.N.; Gladwin, M.T. Sickle-cell disease. Lancet 2010, 376, 2018–2031.
  5. Kato, G.J.; Onyekwere, O.C.; Gladwin, M.T. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr. Hematol. Oncol. 2007, 24, 159–170.
  6. Kato, G.J.; Steinberg, M.H.; Gladwin, M.T. Intravascular hemolysis and the pathophysiology of sickle cell disease. J. Clin. Investig. 2017, 127, 750–760.
  7. Chow, A.; Huggins, M.; Ahmed, J.; Hashimoto, D.; Lucas, D.; Kunisaki, Y.; Pinho, S.; Leboeuf, M.; Noizat, C.; van Rooijen, N.; et al. CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat. Med. 2013, 19, 429–436.
  8. Yoshida, H.; Kawane, K.; Koike, M.; Mori, Y.; Uchiyama, Y.; Nagata, S. Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells. Nature 2005, 437, 754–758.
  9. Rhodes, M.M.; Kopsombut, P.; Bondurant, M.C.; Price, J.O.; Koury, M.J. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood 2008, 111, 1700–1708.
  10. Heideveld, E.; Hampton-O’Neil, L.A.; Cross, S.J.; van Alphen, F.P.J.; van den Biggelaar, M.; Toye, A.M.; van den Akker, E. Glucocorticoids induce differentiation of monocytes towards macrophages that share functional and phenotypical aspects with erythroblastic island macrophages. Haematologica 2018, 103, 395–405.
  11. Fabriek, B.O.; Polfliet, M.M.; Vloet, R.P.; van der Schors, R.C.; Ligtenberg, A.J.; Weaver, L.K.; Geest, C.; Matsuno, K.; Moestrup, S.K.; Dijkstra, C.D.; et al. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood 2007, 109, 5223–5229.
  12. Sadahira, Y.; Yoshino, T.; Monobe, Y. Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J. Exp. Med. 1995, 181, 411–415.
  13. Lee, G.; Lo, A.; Short, S.A.; Mankelow, T.J.; Spring, F.; Parsons, S.F.; Yazdanbakhsh, K.; Mohandas, N.; Anstee, D.J.; Chasis, J.A. Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood 2006, 108, 2064–2071.
  14. Hampton-O’Neil, L.A.; Severn, C.E.; Cross, S.J.; Gurung, S.; Nobes, C.D.; Toye, A.M. Ephrin/Eph receptor interaction facilitates macrophage recognition of differentiating human erythroblasts. Haematologica 2020, 105, 914–924.
  15. Wei, Q.; Boulais, P.E.; Zhang, D.; Pinho, S.; Tanaka, M.; Frenette, P.S. Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands. Blood 2019, 133, 1222–1232.
  16. Lee, G.; Spring, F.A.; Parsons, S.F.; Mankelow, T.J.; Peters, L.L.; Koury, M.J.; Mohandas, N.; Anstee, D.J.; Chasis, J.A. Novel secreted isoform of adhesion molecule ICAM-4: Potential regulator of membrane-associated ICAM-4 interactions. Blood 2003, 101, 1790–1797.
  17. Seu, K.G.; Papoin, J.; Fessler, R.; Hom, J.; Huang, G.; Mohandas, N.; Blanc, L.; Kalfa, T.A. Unraveling Macrophage Heterogeneity in Erythroblastic Islands. Front. Immunol. 2017, 8, 1140.
  18. Yeo, J.H.; McAllan, B.M.; Fraser, S.T. Scanning Electron Microscopy Reveals Two Distinct Classes of Erythroblastic Island Isolated from Adult Mammalian Bone Marrow. Microsc. Microanal. 2016, 22, 368–378.
  19. Ulyanova, T.; Jiang, Y.; Padilla, S.; Nakamoto, B.; Papayannopoulou, T. Combinatorial and distinct roles of alpha(5) and alpha(4) integrins in stress erythropoiesis in mice. Blood 2011, 117, 975–985.
  20. Tolu, S.S.; Wang, K.; Yan, Z.; Zhang, S.; Roberts, K.; Crouch, A.S.; Sebastian, G.; Chaitowitz, M.; Fornari, E.D.; Schwechter, E.M.; et al. Characterization of Hematopoiesis in Sickle Cell Disease by Prospective Isolation of Stem and Progenitor Cells. Cells 2020, 9, 2159.
  21. Heideveld, E.; Masiello, F.; Marra, M.; Esteghamat, F.; Yagci, N.; von Lindern, M.; Migliaccio, A.R.; van den Akker, E. CD14+ cells from peripheral blood positively regulate hematopoietic stem and progenitor cell survival resulting in increased erythroid yield. Haematologica 2015, 100, 1396–1406.
  22. Liu, Y.; Zhong, H.; Bao, W.; Mendelson, A.; An, X.; Shi, P.; Chou, S.T.; Manwani, D.; Yazdanbakhsh, K. Patrolling monocytes scavenge endothelial-adherent sickle RBCs: A novel mechanism of inhibition of vaso-occlusion in SCD. Blood 2019, 134, 579–590.
  23. Yang, C.; Endoh, M.; Tan, D.Q.; Nakamura-Ishizu, A.; Takihara, Y.; Matsumura, T.; Suda, T. Mitochondria transfer from early stages of erythroblasts to their macrophage niche via tunnelling nanotubes. Br. J. Haematol. 2021, 193, 1260–1274.
  24. Jagadeeswaran, R.; Vazquez, B.A.; Thiruppathi, M.; Ganesh, B.B.; Ibanez, V.; Cui, S.; Engel, J.D.; Diamond, A.M.; Molokie, R.E.; DeSimone, J.; et al. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp. Hematol. 2017, 50, 46–52.
  25. Moriconi, C.; Dzieciatkowska, M.; Roy, M.; D’Alessandro, A.; Roingeard, P.; Lee, J.Y.; Gibb, D.R.; Tredicine, M.; McGill, M.A.; Qiu, A.; et al. Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease. Br. J. Haematol. 2022, 198, 574–586.
  26. Kawane, K.; Fukuyama, H.; Kondoh, G.; Takeda, J.; Ohsawa, Y.; Uchiyama, Y.; Nagata, S. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 2001, 292, 1546–1549.
  27. Cao, Y.A.; Kusy, S.; Luong, R.; Wong, R.J.; Stevenson, D.K.; Contag, C.H. Heme oxygenase-1 deletion affects stress erythropoiesis. PLoS ONE 2011, 6, e20634.
  28. Kovtunovych, G.; Eckhaus, M.A.; Ghosh, M.C.; Ollivierre-Wilson, H.; Rouault, T.A. Dysfunction of the heme recycling system in heme oxygenase 1-deficient mice: Effects on macrophage viability and tissue iron distribution. Blood 2010, 116, 6054–6062.
  29. Toobiak, S.; Shaklai, M.; Shaklai, N. Carbon monoxide induced erythroid differentiation of K562 cells mimics the central macrophage milieu in erythroblastic islands. PLoS ONE 2012, 7, e33940.
  30. Sukhbaatar, N.; Weichhart, T. Iron Regulation: Macrophages in Control. Pharmaceuticals 2018, 11, 137.
  31. Leimberg, M.J.; Prus, E.; Konijn, A.M.; Fibach, E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. J. Cell. Biochem. 2008, 103, 1211–1218.
  32. Nyffenegger, N.; Zennadi, R.; Kalleda, N.; Flace, A.; Ingoglia, G.; Buzzi, R.M.; Doucerain, C.; Buehler, P.W.; Schaer, D.J.; Durrenberger, F.; et al. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood 2022, 140, 769–781.
  33. Li, W.; Wang, Y.; Zhao, H.; Zhang, H.; Xu, Y.; Wang, S.; Guo, X.; Huang, Y.; Zhang, S.; Han, Y.; et al. Identification and transcriptome analysis of erythroblastic island macrophages. Blood 2019, 134, 480–491.
  34. Mukherjee, K.; Bieker, J.J. Transcriptional Control of Gene Expression and the Heterogeneous Cellular Identity of Erythroblastic Island Macrophages. Front. Genet. 2021, 12, 756028.
  35. Lopez-Yrigoyen, M.; Yang, C.T.; Fidanza, A.; Cassetta, L.; Taylor, A.H.; McCahill, A.; Sellink, E.; von Lindern, M.; van den Akker, E.; Mountford, J.C.; et al. Genetic programming of macrophages generates an in vitro model for the human erythroid island niche. Nat. Commun. 2019, 10, 881.
  36. Mukherjee, K.; Xue, L.; Planutis, A.; Gnanapragasam, M.N.; Chess, A.; Bieker, J.J. EKLF/KLF1 expression defines a unique macrophage subset during mouse erythropoiesis. eLife 2021, 10, e61070.
  37. Porcu, S.; Manchinu, M.F.; Marongiu, M.F.; Sogos, V.; Poddie, D.; Asunis, I.; Porcu, L.; Marini, M.G.; Moi, P.; Cao, A.; et al. Klf1 affects DNase II-alpha expression in the central macrophage of a fetal liver erythroblastic island: A non-cell-autonomous role in definitive erythropoiesis. Mol. Cell. Biol. 2011, 31, 4144–4154.
  38. Lu, Y.; Basatemur, G.; Scott, I.C.; Chiarugi, D.; Clement, M.; Harrison, J.; Jugdaohsingh, R.; Yu, X.; Newland, S.A.; Jolin, H.E.; et al. Interleukin-33 Signaling Controls the Development of Iron-Recycling Macrophages. Immunity 2020, 52, 782–793.e5.
  39. Wei, J.; Zhao, J.; Schrott, V.; Zhang, Y.; Gladwin, M.; Bullock, G.; Zhao, Y. Red Blood Cells Store and Release Interleukin-33. J. Investig. Med. 2015, 63, 806–810.
  40. Miyagawa, S.; Kobayashi, M.; Konishi, N.; Sato, T.; Ueda, K. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br. J. Haematol. 2000, 109, 555–562.
  41. Salgar, S.; Bolivar, B.E.; Flanagan, J.M.; Anum, S.J.; Bouchier-Hayes, L. The NLRP3 inflammasome fires up heme-induced inflammation in hemolytic conditions. Transl. Res. 2023, 252, 34–44.
  42. Ramos, P.; Casu, C.; Gardenghi, S.; Breda, L.; Crielaard, B.J.; Guy, E.; Marongiu, M.F.; Gupta, R.; Levine, R.L.; Abdel-Wahab, O.; et al. Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia. Nat. Med. 2013, 19, 437–445.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback